GRI Bio receives FDA 7-year exclusivity designation
Share
- GRI Bio received FDA Orphan Drug Designation for its idiopathic pulmonary fibrosis drug candidate, GRI-0621.
- The regulatory designation qualifies the company for tax credits, fee waivers, and potential seven-year market exclusivity.
- The company aims to leverage enhanced regulatory interactions to advance its clinical pipeline following a successful Phase 2a trial.
GRI Bio (NASDAQ:GRI) received FDA Orphan Drug Designation for its idiopathic pulmonary fibrosis drug candidate, GRI-0621.
This regulatory milestone follows standard development protocols for treating this chronic lung disease.
The company stated that the new designation provides eligibility for seven years of United States market exclusivity.
Additional incentives under the program include clinical trial tax credits, prescription drug user fee waivers, and enhanced regulatory interactions.
The regulatory decision was supported by data from a 35-patient Phase 2a trial where the treatment met all endpoints.
